Latent Health raises $80M
Latent Health closed an $80M Series A for healthcare AI out of San Francisco — that level of funding usually coincides with scaling inference and compliance tooling. The raise positions them to start buying or co‑locating inference hardware. (x.com)
Round was co‑led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst and Y Combinator. (latenthealth.com)) The company was founded by Rishabh Jain and Sriram Somasundaram in November 2022, with Somasundaram serving as co‑CEO. (forbes.com)) Latent reports more than $20 million in annualized revenue and a post‑round valuation around $600 million, according to people familiar with the deal. (forbes.com)) Its “clinical reasoning engine” ingests doctor notes, labs and images to interpret drug criteria, compile evidence and automate workflows, and the system can even place status calls to payers on a provider’s behalf. (latenthealth.com)) The startup says it has scaled from 4 to over 45 health‑system partners, now serving roughly half of the top 20 U.S. health systems including Yale New Haven, UCSF, Mount Sinai and Vanderbilt. (latenthealth.com)) Latent is focused on prior authorization for specialty therapies — a market Forbes estimates at about $200 billion — and is targeting the administrative burden around high‑cost specialty drug approvals. (forbes.com)) Company statements and trade coverage say the capital will be used to deepen the platform, grow headcount and expand partnerships with health systems and pharmacies. (mobihealthnews.com))
